0.4852
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| VBI Vaccines Inc | VBIV | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.4852 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.4852 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.48 - 2.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.4852 | USD |
Period:
Draw Mode:
VBI Vaccines Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 125.31M | 258.26M | 191.22M | $ 631.00k | $ - | -0.27 | -1.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 0.60% |
VBI Vaccines News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VBIV Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.6093 | 0.63 | 0.48 | 0.5219493 | 1,684,605 | -0.1241 | -20.37% |
| 1 Month | 0.67 | 0.699 | 0.48 | 0.5743 | 1,068,013 | -0.1848 | -27.58% |
| 3 Months | 0.82 | 0.85 | 0.48 | 0.6610208 | 850,906 | -0.3348 | -40.83% |
| 6 Months | 0.9489 | 1.35 | 0.48 | 0.8061563 | 1,511,931 | -0.4637 | -48.87% |
| 1 Year | 2.39 | 2.75 | 0.48 | 1.35 | 1,943,754 | -1.90 | -79.7% |
| 3 Years | 0.81 | 7.24 | 0.48 | 2.79 | 5,081,776 | -0.3248 | -40.1% |
| 5 Years | 4.24 | 7.24 | 0.45 | 2.60 | 3,431,108 | -3.75 | -88.56% |
VBI Vaccines Description
| VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology. |